Search by Drug Name or NDC
NDC 68727-0745-01 VYXEOS 100; 44 mg/20mL; mg/20mL Details
VYXEOS 100; 44 mg/20mL; mg/20mL
VYXEOS is a INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Jazz Pharmaceuticals, Inc.. The primary component is CYTARABINE; DAUNORUBICIN.
MedlinePlus Drug Summary
Daunorubicin and cytarabine lipid complex is used to treat certain types of acute myeloid leukemia (AML; a type of cancer of the white blood cells) in adults and children 1 year of age and older. Daunorubicin is in a class of medications called anthracyclines. Cytarabine is in a class of medications called antimetabolites. Daunorubicin and cytarabine lipid complex slows or stops the growth of cancer cells in your body.
Related Packages: 68727-0745-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Daunorubicin and Cytarabine Lipid Complex Injection
Product Information
| NDC | 68727-0745 |
|---|---|
| Product ID | 68727-745_83857dc4-2e28-4030-ac34-87408d28e337 |
| Associated GPIs | 21990002201930 |
| GCN Sequence Number | 077659 |
| GCN Sequence Number Description | daunorubicin/cytarabine lipos VIAL 44MG-100MG INTRAVEN |
| HIC3 | V33 |
| HIC3 Description | ANTINEOPLASTIC - ANTIBIOTIC AND ANTIMETABOLITE |
| GCN | 43747 |
| HICL Sequence Number | 044461 |
| HICL Sequence Number Description | DAUNORUBICIN/CYTARABINE LIPOSOMAL |
| Brand/Generic | Brand |
| Proprietary Name | VYXEOS |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | (daunorubicin and cytarabine) liposome |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 100; 44 |
| Active Ingredient Units | mg/20mL; mg/20mL |
| Substance Name | CYTARABINE; DAUNORUBICIN |
| Labeler Name | Jazz Pharmaceuticals, Inc. |
| Pharmaceutical Class | Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Nucleic Acid Synthesis Inhibitors [MoA], Nucleoside Metabolic Inhibitor [EPC], Topoisomerase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA209401 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 68727-0745-01 (68727074501)
| NDC Package Code | 68727-745-01 |
|---|---|
| Billing NDC | 68727074501 |
| Package | 20 mL in 1 VIAL (68727-745-01) |
| Marketing Start Date | 2017-08-03 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |